カテゴリ： Market Monitor Global, 世界, 医療/バイオ

胃がん治療のグローバル市場展望 2023年-2029年：医療用医薬品、一般用医薬品

■ 英語タイトル：Gastric Cancer Therapy Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23JU5578）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23JU5578
■ 発行日：2023年6月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆医療
■ ページ数：120
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[胃がん治療のグローバル市場展望 2023年-2029年：医療用医薬品、一般用医薬品]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の胃がん治療市場規模と予測を収録しています。・世界の胃がん治療市場：売上、2018年-2023年、2024年-2029年
・世界の胃がん治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の胃がん治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「医療用医薬品」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

胃がん治療のグローバル主要企業は、Novartis AG、 Glaxo SmithKline Plc、 Roche Holding Limited、 AptarGroup Incorporated、 Squibb Company、 Boston Scientific Corporation、 Pfizer.、 Agilent Technologies, Inc.、 Illumina, Inc.、 Thermo Fisher Scientific, Inc.、 General Electric Company、 BD、 Abbott、 QIAGEN、 Siemens Healthcare GmbH、 F. Hoffmann-La Roche Ltd.、 Koninklijke Philips N.V.、 Eli Lilly and Company、 F. Hoffmann-La Roche Ltd.、 Merck KGaAなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、胃がん治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の胃がん治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の胃がん治療市場：タイプ別市場シェア、2022年
・医療用医薬品、一般用医薬品

世界の胃がん治療市場：用途別、2018年-2023年、2024年-2029年
世界の胃がん治療市場：用途別市場シェア、2022年
・オンライン販売、オフライン販売

世界の胃がん治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の胃がん治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における胃がん治療のグローバル売上、2018年-2023年
・主要企業における胃がん治療のグローバル売上シェア、2022年
・主要企業における胃がん治療のグローバル販売量、2018年-2023年
・主要企業における胃がん治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Novartis AG、 Glaxo SmithKline Plc、 Roche Holding Limited、 AptarGroup Incorporated、 Squibb Company、 Boston Scientific Corporation、 Pfizer.、 Agilent Technologies, Inc.、 Illumina, Inc.、 Thermo Fisher Scientific, Inc.、 General Electric Company、 BD、 Abbott、 QIAGEN、 Siemens Healthcare GmbH、 F. Hoffmann-La Roche Ltd.、 Koninklijke Philips N.V.、 Eli Lilly and Company、 F. Hoffmann-La Roche Ltd.、 Merck KGaA

*************************************************************

・調査・分析レポートの概要
胃がん治療市場の定義
市場セグメント
世界の胃がん治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の胃がん治療市場規模
世界の胃がん治療市場規模：2022年 VS 2029年
世界の胃がん治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの胃がん治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の胃がん治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：医療用医薬品、一般用医薬品
胃がん治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：オンライン販売、オフライン販売
胃がん治療の用途別グローバル売上・予測

・地域別市場分析
地域別胃がん治療市場規模 2022年と2029年
地域別胃がん治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Novartis AG、 Glaxo SmithKline Plc、 Roche Holding Limited、 AptarGroup Incorporated、 Squibb Company、 Boston Scientific Corporation、 Pfizer.、 Agilent Technologies, Inc.、 Illumina, Inc.、 Thermo Fisher Scientific, Inc.、 General Electric Company、 BD、 Abbott、 QIAGEN、 Siemens Healthcare GmbH、 F. Hoffmann-La Roche Ltd.、 Koninklijke Philips N.V.、 Eli Lilly and Company、 F. Hoffmann-La Roche Ltd.、 Merck KGaA
...

Gastric Cancer Therapy is caused by uncontrolled abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as Gastric Cancer Therapy or stomach cancer. Diet and stomach disorders are both risk factors for Gastric Cancer Therapy. Stomach pain, poor appetite, weight loss, indigestions, nausea, vomiting with or without blood are some of the symptoms of Gastric Cancer Therapy.
This report aims to provide a comprehensive presentation of the global market for Gastric Cancer Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastric Cancer Therapy. This report contains market size and forecasts of Gastric Cancer Therapy in global, including the following market information:
Global Gastric Cancer Therapy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Gastric Cancer Therapy Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Gastric Cancer Therapy companies in 2022 (%)
The global Gastric Cancer Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Prescription Drugs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Gastric Cancer Therapy include Novartis AG, Glaxo SmithKline Plc, Roche Holding Limited, AptarGroup Incorporated, Squibb Company, Boston Scientific Corporation, Pfizer., Agilent Technologies, Inc. and Illumina, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gastric Cancer Therapy manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gastric Cancer Therapy Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Gastric Cancer Therapy Market Segment Percentages, by Type, 2022 (%)
Prescription Drugs
Non-Prescription Drugs
Global Gastric Cancer Therapy Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Gastric Cancer Therapy Market Segment Percentages, by Application, 2022 (%)
Online Sales
Offline Sales
Global Gastric Cancer Therapy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Gastric Cancer Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gastric Cancer Therapy revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Gastric Cancer Therapy revenues share in global market, 2022 (%)
Key companies Gastric Cancer Therapy sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Gastric Cancer Therapy sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis AG
Glaxo SmithKline Plc
Roche Holding Limited
AptarGroup Incorporated
Squibb Company
Boston Scientific Corporation
Pfizer.
Agilent Technologies, Inc.
Illumina, Inc.
Thermo Fisher Scientific, Inc.
General Electric Company
BD
Abbott
QIAGEN
Siemens Healthcare GmbH
F. Hoffmann-La Roche Ltd.
Koninklijke Philips N.V.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Merck KGaA
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gastric Cancer Therapy, market overview.
Chapter 2: Global Gastric Cancer Therapy market size in revenue and volume.
Chapter 3: Detailed analysis of Gastric Cancer Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gastric Cancer Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Gastric Cancer Therapy capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Gastric Cancer Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gastric Cancer Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gastric Cancer Therapy Overall Market Size
2.1 Global Gastric Cancer Therapy Market Size: 2022 VS 2029
2.2 Global Gastric Cancer Therapy Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Gastric Cancer Therapy Sales: 2018-2029
3 Company Landscape
3.1 Top Gastric Cancer Therapy Players in Global Market
3.2 Top Global Gastric Cancer Therapy Companies Ranked by Revenue
3.3 Global Gastric Cancer Therapy Revenue by Companies
3.4 Global Gastric Cancer Therapy Sales by Companies
3.5 Global Gastric Cancer Therapy Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Gastric Cancer Therapy Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Gastric Cancer Therapy Product Type
3.8 Tier 1, Tier 2 and Tier 3 Gastric Cancer Therapy Players in Global Market
3.8.1 List of Global Tier 1 Gastric Cancer Therapy Companies
3.8.2 List of Global Tier 2 and Tier 3 Gastric Cancer Therapy Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Gastric Cancer Therapy Market Size Markets, 2022 & 2029
4.1.2 Prescription Drugs
4.1.3 Non-Prescription Drugs
4.2 By Type – Global Gastric Cancer Therapy Revenue & Forecasts
4.2.1 By Type – Global Gastric Cancer Therapy Revenue, 2018-2023
4.2.2 By Type – Global Gastric Cancer Therapy Revenue, 2024-2029
4.2.3 By Type – Global Gastric Cancer Therapy Revenue Market Share, 2018-2029
4.3 By Type – Global Gastric Cancer Therapy Sales & Forecasts
4.3.1 By Type – Global Gastric Cancer Therapy Sales, 2018-2023
4.3.2 By Type – Global Gastric Cancer Therapy Sales, 2024-2029
4.3.3 By Type – Global Gastric Cancer Therapy Sales Market Share, 2018-2029
4.4 By Type – Global Gastric Cancer Therapy Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Gastric Cancer Therapy Market Size, 2022 & 2029
5.1.2 Online Sales
5.1.3 Offline Sales
5.2 By Application – Global Gastric Cancer Therapy Revenue & Forecasts
5.2.1 By Application – Global Gastric Cancer Therapy Revenue, 2018-2023
5.2.2 By Application – Global Gastric Cancer Therapy Revenue, 2024-2029
5.2.3 By Application – Global Gastric Cancer Therapy Revenue Market Share, 2018-2029
5.3 By Application – Global Gastric Cancer Therapy Sales & Forecasts
5.3.1 By Application – Global Gastric Cancer Therapy Sales, 2018-2023
5.3.2 By Application – Global Gastric Cancer Therapy Sales, 2024-2029
5.3.3 By Application – Global Gastric Cancer Therapy Sales Market Share, 2018-2029
5.4 By Application – Global Gastric Cancer Therapy Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Gastric Cancer Therapy Market Size, 2022 & 2029
6.2 By Region – Global Gastric Cancer Therapy Revenue & Forecasts
6.2.1 By Region – Global Gastric Cancer Therapy Revenue, 2018-2023
6.2.2 By Region – Global Gastric Cancer Therapy Revenue, 2024-2029
6.2.3 By Region – Global Gastric Cancer Therapy Revenue Market Share, 2018-2029
6.3 By Region – Global Gastric Cancer Therapy Sales & Forecasts
6.3.1 By Region – Global Gastric Cancer Therapy Sales, 2018-2023
6.3.2 By Region – Global Gastric Cancer Therapy Sales, 2024-2029
6.3.3 By Region – Global Gastric Cancer Therapy Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Gastric Cancer Therapy Revenue, 2018-2029
6.4.2 By Country – North America Gastric Cancer Therapy Sales, 2018-2029
6.4.3 US Gastric Cancer Therapy Market Size, 2018-2029
6.4.4 Canada Gastric Cancer Therapy Market Size, 2018-2029
6.4.5 Mexico Gastric Cancer Therapy Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Gastric Cancer Therapy Revenue, 2018-2029
6.5.2 By Country – Europe Gastric Cancer Therapy Sales, 2018-2029
6.5.3 Germany Gastric Cancer Therapy Market Size, 2018-2029
6.5.4 France Gastric Cancer Therapy Market Size, 2018-2029
6.5.5 U.K. Gastric Cancer Therapy Market Size, 2018-2029
6.5.6 Italy Gastric Cancer Therapy Market Size, 2018-2029
6.5.7 Russia Gastric Cancer Therapy Market Size, 2018-2029
6.5.8 Nordic Countries Gastric Cancer Therapy Market Size, 2018-2029
6.5.9 Benelux Gastric Cancer Therapy Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Gastric Cancer Therapy Revenue, 2018-2029
6.6.2 By Region – Asia Gastric Cancer Therapy Sales, 2018-2029
6.6.3 China Gastric Cancer Therapy Market Size, 2018-2029
6.6.4 Japan Gastric Cancer Therapy Market Size, 2018-2029
6.6.5 South Korea Gastric Cancer Therapy Market Size, 2018-2029
6.6.6 Southeast Asia Gastric Cancer Therapy Market Size, 2018-2029
6.6.7 India Gastric Cancer Therapy Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Gastric Cancer Therapy Revenue, 2018-2029
6.7.2 By Country – South America Gastric Cancer Therapy Sales, 2018-2029
6.7.3 Brazil Gastric Cancer Therapy Market Size, 2018-2029
6.7.4 Argentina Gastric Cancer Therapy Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Gastric Cancer Therapy Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Gastric Cancer Therapy Sales, 2018-2029
6.8.3 Turkey Gastric Cancer Therapy Market Size, 2018-2029
6.8.4 Israel Gastric Cancer Therapy Market Size, 2018-2029
6.8.5 Saudi Arabia Gastric Cancer Therapy Market Size, 2018-2029
6.8.6 UAE Gastric Cancer Therapy Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Novartis AG
7.1.1 Novartis AG Company Summary
7.1.2 Novartis AG Business Overview
7.1.3 Novartis AG Gastric Cancer Therapy Major Product Offerings
7.1.4 Novartis AG Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.1.5 Novartis AG Key News & Latest Developments
7.2 Glaxo SmithKline Plc
7.2.1 Glaxo SmithKline Plc Company Summary
7.2.2 Glaxo SmithKline Plc Business Overview
7.2.3 Glaxo SmithKline Plc Gastric Cancer Therapy Major Product Offerings
7.2.4 Glaxo SmithKline Plc Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.2.5 Glaxo SmithKline Plc Key News & Latest Developments
7.3 Roche Holding Limited
7.3.1 Roche Holding Limited Company Summary
7.3.2 Roche Holding Limited Business Overview
7.3.3 Roche Holding Limited Gastric Cancer Therapy Major Product Offerings
7.3.4 Roche Holding Limited Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.3.5 Roche Holding Limited Key News & Latest Developments
7.4 AptarGroup Incorporated
7.4.1 AptarGroup Incorporated Company Summary
7.4.2 AptarGroup Incorporated Business Overview
7.4.3 AptarGroup Incorporated Gastric Cancer Therapy Major Product Offerings
7.4.4 AptarGroup Incorporated Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.4.5 AptarGroup Incorporated Key News & Latest Developments
7.5 Squibb Company
7.5.1 Squibb Company Company Summary
7.5.2 Squibb Company Business Overview
7.5.3 Squibb Company Gastric Cancer Therapy Major Product Offerings
7.5.4 Squibb Company Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.5.5 Squibb Company Key News & Latest Developments
7.6 Boston Scientific Corporation
7.6.1 Boston Scientific Corporation Company Summary
7.6.2 Boston Scientific Corporation Business Overview
7.6.3 Boston Scientific Corporation Gastric Cancer Therapy Major Product Offerings
7.6.4 Boston Scientific Corporation Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.6.5 Boston Scientific Corporation Key News & Latest Developments
7.7 Pfizer.
7.7.1 Pfizer. Company Summary
7.7.2 Pfizer. Business Overview
7.7.3 Pfizer. Gastric Cancer Therapy Major Product Offerings
7.7.4 Pfizer. Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.7.5 Pfizer. Key News & Latest Developments
7.8 Agilent Technologies, Inc.
7.8.1 Agilent Technologies, Inc. Company Summary
7.8.2 Agilent Technologies, Inc. Business Overview
7.8.3 Agilent Technologies, Inc. Gastric Cancer Therapy Major Product Offerings
7.8.4 Agilent Technologies, Inc. Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.8.5 Agilent Technologies, Inc. Key News & Latest Developments
7.9 Illumina, Inc.
7.9.1 Illumina, Inc. Company Summary
7.9.2 Illumina, Inc. Business Overview
7.9.3 Illumina, Inc. Gastric Cancer Therapy Major Product Offerings
7.9.4 Illumina, Inc. Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.9.5 Illumina, Inc. Key News & Latest Developments
7.10 Thermo Fisher Scientific, Inc.
7.10.1 Thermo Fisher Scientific, Inc. Company Summary
7.10.2 Thermo Fisher Scientific, Inc. Business Overview
7.10.3 Thermo Fisher Scientific, Inc. Gastric Cancer Therapy Major Product Offerings
7.10.4 Thermo Fisher Scientific, Inc. Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.10.5 Thermo Fisher Scientific, Inc. Key News & Latest Developments
7.11 General Electric Company
7.11.1 General Electric Company Company Summary
7.11.2 General Electric Company Gastric Cancer Therapy Business Overview
7.11.3 General Electric Company Gastric Cancer Therapy Major Product Offerings
7.11.4 General Electric Company Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.11.5 General Electric Company Key News & Latest Developments
7.12 BD
7.12.1 BD Company Summary
7.12.2 BD Gastric Cancer Therapy Business Overview
7.12.3 BD Gastric Cancer Therapy Major Product Offerings
7.12.4 BD Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.12.5 BD Key News & Latest Developments
7.13 Abbott
7.13.1 Abbott Company Summary
7.13.2 Abbott Gastric Cancer Therapy Business Overview
7.13.3 Abbott Gastric Cancer Therapy Major Product Offerings
7.13.4 Abbott Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.13.5 Abbott Key News & Latest Developments
7.14 QIAGEN
7.14.1 QIAGEN Company Summary
7.14.2 QIAGEN Business Overview
7.14.3 QIAGEN Gastric Cancer Therapy Major Product Offerings
7.14.4 QIAGEN Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.14.5 QIAGEN Key News & Latest Developments
7.15 Siemens Healthcare GmbH
7.15.1 Siemens Healthcare GmbH Company Summary
7.15.2 Siemens Healthcare GmbH Business Overview
7.15.3 Siemens Healthcare GmbH Gastric Cancer Therapy Major Product Offerings
7.15.4 Siemens Healthcare GmbH Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.15.5 Siemens Healthcare GmbH Key News & Latest Developments
7.16 F. Hoffmann-La Roche Ltd.
7.16.1 F. Hoffmann-La Roche Ltd. Company Summary
7.16.2 F. Hoffmann-La Roche Ltd. Business Overview
7.16.3 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Major Product Offerings
7.16.4 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.16.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.17 Koninklijke Philips N.V.
7.17.1 Koninklijke Philips N.V. Company Summary
7.17.2 Koninklijke Philips N.V. Business Overview
7.17.3 Koninklijke Philips N.V. Gastric Cancer Therapy Major Product Offerings
7.17.4 Koninklijke Philips N.V. Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.17.5 Koninklijke Philips N.V. Key News & Latest Developments
7.18 Eli Lilly and Company
7.18.1 Eli Lilly and Company Company Summary
7.18.2 Eli Lilly and Company Business Overview
7.18.3 Eli Lilly and Company Gastric Cancer Therapy Major Product Offerings
7.18.4 Eli Lilly and Company Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.18.5 Eli Lilly and Company Key News & Latest Developments
7.19 F. Hoffmann-La Roche Ltd.
7.19.1 F. Hoffmann-La Roche Ltd. Company Summary
7.19.2 F. Hoffmann-La Roche Ltd. Business Overview
7.19.3 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Major Product Offerings
7.19.4 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.19.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.20 Merck KGaA
7.20.1 Merck KGaA Company Summary
7.20.2 Merck KGaA Business Overview
7.20.3 Merck KGaA Gastric Cancer Therapy Major Product Offerings
7.20.4 Merck KGaA Gastric Cancer Therapy Sales and Revenue in Global (2018-2023)
7.20.5 Merck KGaA Key News & Latest Developments
8 Global Gastric Cancer Therapy Production Capacity, Analysis
8.1 Global Gastric Cancer Therapy Production Capacity, 2018-2029
8.2 Gastric Cancer Therapy Production Capacity of Key Manufacturers in Global Market
8.3 Global Gastric Cancer Therapy Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Gastric Cancer Therapy Supply Chain Analysis
10.1 Gastric Cancer Therapy Industry Value Chain
10.2 Gastric Cancer Therapy Upstream Market
10.3 Gastric Cancer Therapy Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Gastric Cancer Therapy Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 下痢止めのグローバル市場展望 2023年-2029年：医療用医薬品、一般用医薬品
  • 非オピオイドパッチのグローバル市場2023：医療用医薬品、一般用医薬品
  • 末梢作用抗肥満薬のグローバル市場2023：医療用医薬品、一般用医薬品
  • 痛み治療注射のグローバル市場2023：一般用医薬品、医療用医薬品
  • 時差ボケ治療薬のグローバル市場2023：医療用医薬品、一般用医薬品
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23JU5578 )"胃がん治療のグローバル市場展望 2023年-2029年：医療用医薬品、一般用医薬品" (英文：Gastric Cancer Therapy Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。